Patients who are not up to date with screening
are at increased risk of CRC mortality1

Did you know?

Over 75% of people who died from CRC
were not up to date with screening1

CRC remains the second-leading
cause of cancer-related deaths in
the United States.2

Significantly fewer patients survive when they are diagnosed
in a later stage2,3

5-YEAR SURVIVAL RATE

BASED ON STAGE OF DIAGNOSIS2,3

Early Stage
(I-II)
90%
Late Stage
(IV)
14%
Sadly, low screening compliance may contribute to over half of patients
getting diagnosed after their disease has spread.4,5

CRC screening compliance rates remain low despite current screening options being offered to patients6

Many factors can prevent patient follow-through7-10

 Stool-based testColonoscopy
Barriers
Stool-based test
  • Discomfort or disgust with handling stool
  • Inconvenience of collecting and mailing stool sample
  • Apprehension about accurately completing a test at home
14-67%11,12
Compliance rate
Colonoscopy
  • Fear of an invasive procedure and associated risk
  • Discomfort with bowel prep
  • Burden and time required for an inpatient procedure, including prep and recovery time
38-50%8,12
Compliance rate
Compliance
rates
14-67%11,1238-50%8,12
Increase CRC
screening
compliance with
an accurate
blood-based
approach.
Simply done.13-15Test tube with blood.

Sign up to receive the latest updates on ShieldTM

By clicking the button above, you agree to receive
periodic product-related updates via email from
Guardant Health.

References1. Doubeni CA, Fedewa SA, Levin TR, et al. Modifiable failures in the colorectal cancer screening process and their association with risk of death. Gastroenterology. 2019;156(1):63-74. doi:10.1053/j.gastro.2018.09.040 2. American Society of Clinical Oncology. Colorectal cancer: statistics. Cancer.net website. Updated January 2021. Accessed May 10, 2021. https://www.cancer.net/cancer-types/colorectal-cancer/statistics 3. American Cancer Society. Colorectal cancer facts & figures 2017-2019. Accessed April 20, 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2017-2019.pdf 4. National Cancer Institute. Colon and rectum stage distribution of SEER incidence cases, 2009-2018. Accessed November 10, 2021. https://seer.cancer.gov/explorer/application.html?site=20&data_type=1&graph_type=4&compareBy=sex&chk_sex_3=3&chk_sex_2=2&race=1&age_range=1&advopt_precision=1 5. Andrew AS, Parker S, Anderson JC, et al. Risk factors for diagnosis of colorectal cancer at a late stage: a population-based study. J Gen Intern Med. 2018;33(12):2100-2105. doi:10.1007/s11606-018-4648-7 6. Centers for Disease Control and Prevention. Cost-effectiveness of colorectal cancer interventions. Updated August 18, 2021. Accessed December 7, 2021. https://www.cdc.gov/chronicdisease/programs-impact/pop/colorectal-cancer.htm 7. Liles EG, Coronado GD, Perrin N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: a randomized trial. Cancer Treat Res Comm. 2017;10:27-31. doi:10.1016/j.ctarc.2016.12.004 8. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20(11):989-995. doi:10.1111/j.1525-1497.2005.00164.x 9. Parks P. Innovation in colorectal cancer screening - there has to be a better way. Am J Manag Care. Published October 9, 2017. Accessed September 17, 2021. https://www.ajmc.com/view/innovation-in-colorectal-cancer-screening-there-has-to-be-a-better-way 10. American Society of Clinical Oncology. Colonoscopy. Cancer.net website. Updated December 2019. Accessed December 7, 2021. https://www.cancer.net/navigating-cancer-care/diagnosing-cancer/tests-and-procedures/colonoscopy 11. Gellad ZF, Stechuchak KM, Fisher DA, et al. Longitudinal adherence to fecal occult blood testing impacts colorectal cancer screening quality. Am J Gastroenterol. 2011;106(6):1125-1134. doi:10.1038/ajg.2011.11 12. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172(7):575-582. doi:10.1001/archinternmed.2012.332 13. Adler A, Geiger S, Keil A, et al. Improving compliance to colorectal cancer screening using blood and stool based tests in patients refusing screening colonoscopy in Germany. BMC Gastroenterol. 2014;14:183. doi:10.1186/1471-230X-14-183 14. Kim ST, Raymond VM, Park JO, et al. Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (ctDNA) improves assay sensitivity in early-stage colorectal cancer (CRC). Cancer Res. 2019;79(suppl 13):916. doi:10.1158/1538-7445.AM2019-916 15. Westesson O, Axelrod H, Dean J, et al. Integrated genomic and epigenomic cell-free DNA (cfDNA) analysis for the detection of early-stage colorectal cancer. Cancer Res. 2020;80(suppl 16):2316. doi:10.1158/1538-7445.AM2020-2316